文献速递肝病

整合转录组与基因组分析揭示IFI16变异及表达作为MASLD进展标志物

Integrative transcriptomic and genomic analyses unveil the IFI16 variants and expression as MASLD progression markers.
PubMed 文献 · Hepatology · 2024-02-20

该研究对146例MASLD肝组织样本进行RNA-Seq、132例进行全外显子测序,鉴定出3种转录组亚型(G1-G3),以巨噬细胞驱动的炎症活动为关键区分特征。IFI16(rs6940, A>T, T779S)的表达与遗传变异与该巨噬细胞互作显著相关,体外实验和结构建模显示该变异稳定性更高、与dsDNA结合亲和力更强,并通过IFI16-PYCARD-CASP1通路加剧DNA感应介导的炎症信号。

要点

  • MASLD肝组织可转录组分为G1-G3三亚型,呈逐步病理与分子进展。
  • 巨噬细胞驱动炎症活动是区分亚型的关键特征。
  • IFI16变异(rs6940)通过IFI16-PYCARD-CASP1通路加剧炎症。

核心结论

  • IFI16变异及表达是MASLD进展的关键分子因素,靶向IFI16-PYCARD-CASP1通路可能为MASLD诊疗提供新方向。

研究设计与样本

  • 对MASLD肝组织样本进行RNA-Seq分析(n=146)和全外显子测序(n=132),并结合体外dsDNA-IFI16结合实验与结构建模。

主要发现

  • 鉴定出3种转录组亚型(G1-G3),以巨噬细胞驱动的炎症活动为关键区分特征。
  • IFI16(rs6940, A>T, T779S)的表达与遗传变异与亚型区分性巨噬细胞互作显著相关。
  • 体外实验和结构建模显示IFI16变异较野生型稳定性增加、dsDNA结合亲和力更强。
  • IFI16变异通过线粒体功能障碍相关的IFI16-PYCARD-CASP1通路加剧DNA感应介导的炎症信号。

临床怎么用

  • IFI16变异与表达或可作为MASLD进展的标志物,IFI16-PYCARD-CASP1通路为潜在诊疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad and continuous spectrum of liver diseases ranging from fatty liver to steatohepatitis. The intricate interactions of genetic, epigenetic, and environmental factors in the development and progression of MASLD remain elusive. Here, we aimed to achieve an integrative understanding of the genomic and transcriptomic alterations throughout the progression of MASLD. APPROACH AND RESULTS: RNA-Seq profiling (n = 146) and whole-exome sequencing (n = 132) of MASLD liver tissue samples identified 3 transcriptomic subtypes (G1-G3) of MASLD, which were characterized by stepwise pathological and molecular progression of the disease. Macrophage-driven inflammatory activities were identified as a key feature for differentiating these subtypes. This subtype-discriminating macrophage interplay was significantly associated with both the expression and genetic variation of the dsDNA sensor IFI16 (rs6940, A>T, T779S), establishing it as a fundamental molecular factor in MASLD progression. The in vitro dsDNA-IFI16 binding experiments and structural modeling revealed that the IFI16 variant exhibited increased stability and stronger dsDNA binding affinity compared to the wild-type. Further downstream investigation suggested that the IFI16 variant exacerbated DNA sensing-mediated inflammatory signals through mitochondrial dysfunction-related signaling of the IFI16-PYCARD-CASP1 pathway. CONCLUSIONS: This study unveils a comprehensive understanding of MASLD progression through transcriptomic classification, highlighting the crucial roles of IFI16 variants. Targeting the IFI16-PYCARD-CASP1 pathway may pave the way for the development of novel diagnostics and therapeutics for MASLD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kim D, Shah M, Kim JH, et al. Integrative transcriptomic and genomic analyses unveil the IFI16 variants and expression as MASLD progression markers. Hepatology. 2024. PMID: 38385945. doi:10.1097/HEP.0000000000000805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。